Boundless Bio Doses First Patient with BBI-825 in the P-I/II Study for Cancer Treatment
Shots:
- The P-I/II (STARMAP) study assesses BBI 825's safety, PK, PD biomarkers, preliminary antitumor activity, MTD & RP2D as monotx. & in combination with select targeted therapies
- The part 1 evaluates BBI-825 alone to treat solid tumors, part 2 evaluates BBI 825 combined with encorafenib & cetuximab or adagrasib & cetuximab to treat advanced/metastatic, BRAFV600E or KRASG12C mutated colorectal cancer, respectively & co-occurring resistance gene amplifications while part 3 evaluates anti-tumor activity of the determined RP2D
- BBI-825 is a small molecule that inhibited low double digit nanomolar RNR & tumor growth to prevent & treat amplification-mediated resistance in MAPK pathway-activated tumors in its preclinical study
Ref: Boundless Bio | Image: Boundless Bio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
